Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma.

We have developed a novel replication-competent, oncolytic herpes simplex virus (HSV), named HF10, and have evaluated its anticancer efficacy in a variety of animal models. We report a pilot study of intratumoral injection of HF10 into subcutaneous nodules in patients with head and neck squamous cell carcinoma (HNSCC). HF10 efficiently infected human HNSCC cells and caused extensive tumor cell death without any significant adverse effects, suggesting that HF10 represents a promising therapy for HNSCC in humans.

Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.

Objectives: To investigate the antitumor effects of the oncolytic herpes simplex virus (HSV) type 1 mutant HF10 on human and murine bladder cancer cells (T24 and MBT-2) in vitro and in immunocompetent mouse models.

Methods: In vitro viral oncolytic activity and the replication ability of HF10 were measured in T24 and MBT-2 cells. To evaluate the therapeutic efficacy of HF10, disseminated peritoneal and bladder cancer models using MBT-2 cells were established in C3H/HeJ mice.

Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.

Background And Objectives: Many genetically engineered viruses have been evaluated for their potential as therapeutic agents in the treatment of malignant tumors. We applied a spontaneously generated, highly attenuated herpes simplex virus (HSV) type-1 clone, HF10, to the treatment of breast cancer. In this study, we investigated the ability of HF10 to infect and lyse human and murine breast cancer cells in vitro and tested its efficacy in an immuno-competent animal model of breast cancer.